---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-122282"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T19:07:26.243822+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Alumis updates LUMUS Phase 2 trial timeline on ClinicalTrials.gov

## Summary
- Revised primary completion and study completion dates for LUMUS trial (ESK-001 in SLE) posted November 22, 2024.
- LUMUS is a global, randomized, double-blind, placebo-controlled Phase 2 trial.
- Company states the revisions conform with prior SEC filings and public guidance.
- No specific new dates or financial impact disclosed in the filing.

## SEC filing metadata
- accession: 0001104659-24-122282
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000110465924122282/0001104659-24-122282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000110465924122282/tm2429434d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-122282
- JSON: https://secwatch.observer/filing/0001104659-24-122282.json
- Plain text: https://secwatch.observer/filing/0001104659-24-122282.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.